The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Skid, Elrico - both of you want to throw about various statistics but the only one that matters is the number of subscriptions in the near future. If you pay attention, I am not disputing those numbers are they are available. What I am saying is that it will take time. Neither of you agree so it is fair to ask you in turn what you envision the number will be within a quarter. It is ultimately the true measure of whether or not you know what you are talking about.
All...£1.50 per day is not a lot when you break it down per day but you don't have the option of paying one day at a time. You pay a large amount upfront. My view is that this won't get going until it builds momentum through word of mouth and this will take time. As I said, I would be ecstatic to be proven wrong but am approaching this investment with patience though the share price action as of late seems to indicate that I am in the minority.
Let's make this interesting - what do people expect the number of subscriptions to be in the first 3 months?
Watch out Odysseus - you might be accused of being a "de ramper" by those who spend perhaps too much time on this forum.
I actually think the results are excellent - approx 3 out of 4 experienced noticeable improvement. However, I believe it will take time for people to trust this new supplement and to build a following. I am patient because of the results.
Aqua, I am aware of the extra supply and while it could entice a few more people to try out the product, I still believe that it will take time for subscriptions to take off. Many people will already be paying for current treatments so may adopt a wait and see attitude. I would be happy to be wrong. Regardless, SBTX will have its day eventually as this will be a snowball effect.
Whackery, at £1.5/$2 per day, I expect this to take time to build a loyal following. Many people just do not have that kind of money lying around to experiment but as someone else wrote, give it time for its impact to make its way through chat forums and word of mouth. The trial results are impressive so I have faith that this will eventually make it onto sufferers' radars.
Thanks Floridajoe. As soon as I read that it was in early stage trial, I filed it as something to look at later and moved on.
I recall reading that one of the large pharma companies is working on an inhaled vaccine but that it was early stage.
While admittedly, I am not an active poster here (partly because this stock has been a slow burn for over a year compared to vaccine stocks with their daily twists and turns, partly because I invest mostly in US biotech stocks, and partly b/c I would rather read others' opinions and only post if seeking feedback), being called a closet deramper is a first. Getting into petty arguments is really not my thing.
Thank you belgrano. Indeed, I find your and Elrico's contributions top notch which is why I wanted to set the record straight after reading statements that characterise my comments as personal attacks. All the best.
Thank you Ndn, I hadn't thought of it that way. I only focused on the endpoints but there is always data to be gleaned.
modpod, I was not precise enough and I agree.
Telling someone to "buzz off" is not considered aggressive? You must really struggle to negotiate civilized society.
1. From what I have read, I believe SNG mgt have done their part. However, one HAS to ask and seek other investors' views. That was the point of my post.
2. Atea's mistake is a similar mistake to the one SNG made when pursuing the home trial, in my opinion. I am very pleased of course that we have made it past P2 of Active-2. However, my belief is that SNG distinguishes itself in helping those with acute symptoms. I am surprised you are so upset at what is supported by results and common sense...why spend £1400 on someone with mild flu-like symptoms? My point in posting this was to see if others had simialr views or disagreed.
As for my level of investment - disclosing my exposure was a knee jerk reaction and isn't relevant. Whether I hold 100 shares or 100K shares, the points still hold.
Kevin, I have no idea where your aggressive comment is coming from. Both are things that investors must factor in.
For the record, I have 35,000 shares.
I suppose that I am the "Jimmy" in question though I will say again that you have misinterpreted or confused my comments with others. My criticism is not directed at you Elrico. My criticism is to the IR department of SBTX. Shareholders OWN SBTX and it is the responsibility of management to provide the owners with pertinent information.
Elrico, hold on a minute. Your comments make it appear that my comments are directed at you when they have consistently been a criticism of how the Investor Relations Dep at SBTX fails to engage with its entire shareholder base. The shareholders OWN SBTX and it is the duty of management to keep them informed.
Superritch, thanks for clearing that up. Slight nuance there!
1. From Novavax - don't underestimate the complexity of manufacturing . I truly hope that it is far easier to manufacture nebulisers than vaccines
2. From Atea - the wrong patient target for a good drug can be deadly for a company. We learned this through the home trial and hopefully SPRINTER will provide clear evidence and put an end to questions of effectiveness.
essess, " If we get to approval, RM was looking for a takeover (previous example he gave was Roche paying £8b for Intermune)" ...sorry, I missed that. Did RM really say that if given approval, the aim would be to sell?
Elrico, You misinterpret my comments. No suggestion of a conspiracy, merely pointing out what I see as an unusual comms strategy by the CEO if you or belgrano were able to obtain figures not available elsewhere. Imagine if I were to tell you that if you only bothered to hop on a plane and visit Resmond, WA, Microsoft’s CEO would provide you with sales forecasts not previously made available through an investor call, you would think that questionable no?
Hi Belgrano, while I appreciate the information you provide, as an investor we must all ask. In all my years of investing, I have yet to hear of a situation where a company’s CEO or Investor Relations group chooses to communicate information through someone not associated with the company. I t creates all sorts of potential for insider information and corruption.